January 27, 2017
BMS posts Q4 net profit, revenues driven by Opdivo sales up
Bristol-Myers Squib on Thursday posted fourth quarter net earnings of $1.1 billion, driven ly by increased sales of Opdivo and Eliquis.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Opdivo
January 20, 2017
Bristol-Myers not asking for faster Opdivo/Yervov approval for first-line lung cancer in U.S.
Bristol-Myers Squibb said on Thursday that it won’t seek an accelerated approval for the combination of Opdivo plus Yervoy in first-line lung cancer in the U.S.
January 9, 2017
Innate Pharma cashes $15million milestone payment from Bristol-Myers for lirilumab-Opdivo testing
Bristol-Myers Squibb (BMS) has reached a payment milestone in connection with the licensing deal with Innate Pharma for lirilumab in combination with Opdivo. BMS has paied Innate $15 million.
January 6, 2017
BMS tries out GeneCentric’s Cancer Subtype Platform for Opdivo clinical trials
Bristol-Myers Squibb (BMS) and GeneCentric Diagnostics have teamed up to explore the possibility of GeneCentric’s Cancer Subtype Platform (CSP) could identify translational biomakers for Opdivo, that could help for future clinical trials.
January 5, 2017
BMS, Janssen to test cancer drug together
BMS and Janssen Biotech announced continuation of their work together through a new clinical research.
November 9, 2016
Bristol-Myers, Infinity Pharmaceuticals join forces to test drug in advanced solid tumors
ristol-Myers Squibb Company and Infinity Pharmaceuticals have announced a clinical trial collaboration to evaluate Bristol-Myers Squibb’s Opdivo …
October 9, 2016
No silver lining in failed Bristol cancer drug trail
Bristol-Myers Squibb disappointed investors on Sunday as researchers detailed data for its Opdivo cancer immunotherapy, which was already known to have failed to do better than older chemotherapies in a closely watched clinical trial.
December 17, 2015
Bristol’s drug pricing under fire as UK agency rejects Opdivo
Bristol-Myers Squibb’s closely watched new drug Opdivo, one of the first of a new wave of cancer medicines that boost the immune system, has been rejected as too expensive for treating lung cancer by Britain’s cost watchdog.
November 24, 2015
Bristol-Myres Squid’s Opdivo gets FDA’s nod (kidney cancer)
The U.S. Food and Drug Administration has approved Bristol-Myers Squibb-marketed Opdivo (nivolumab) to treat patients with advanced form of kidney cancer.